Therapeutic Solutions International Reports Augmentation of
Rejuvenating Activity of Cord Blood Plasma by
Pterostilbene
Company Expands Use of
Commercially Available Anti-Inflammatory Nanoparticle Nutraceutical
NanoStilbene™ into Anti-Aging Market
OCEANSIDE, CA --
November 4, 2019 -- InvestorsHub NewsWire
-- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) announced
today new data and a patent
filing suggesting that pterostilbene, the active ingredient in its
commercially available NanoStilbene™
product, augments the
ability
of cord blood plasma to suppress biological properties associated
with aging.
In a series of
laboratory experiments, it was observed that cord blood plasma was
capable of suppressing the expression of beta-galactosidase, a
protein associated with aging. When cord blood plasma was
combined with pterostilbene a significantly greater suppression of
the aging-associated molecule was seen.
"Previous studies
from Stanford University
[1]
and
Harvard
University
[2]
have
shown
that if the circulation of an aged mouse is connected to the
circulation of a young mouse, various factors secreted by young
mice induce an anti-aging/rejuvenating effect on organs
and
tissues
of aged mice. Following this logic, other studies have
demonstrated that human cord blood plasma, when administered to
aged mice results in restoration of brain function and improved
cellular function in the hippocampus
[3]"
said
Dr.
Thomas
Ichim, Board Member of the Company. "Based on our previous
observations of the potent anti-inflammatory properties of our
proprietary pterostilbene formulation in patients[4],
combined
with these new data, we believe that there may be a place for
pterostilbene-based products as an adjuvant to cord blood plasma
regenerative approaches."
The Company believes
that pterostilbene possesses unique antioxidant and cellular
protective activities that are capable of suppressing various
age-associated inflammatory molecules, which in turn allow for the
enhanced regenerative ability of cord blood plasma to mediate
therapeutic effects.
"The unexpected
findings disclosed today are a testimony to the wide range of
activities that pterostilbene based products
exhibit,"
said Timothy Dixon,
President, and CEO of the Company. "While we are currently focused
on our oncology applications, we are eager to collaborate with
industry and academia to continue advancing knowledge and
applications of this highly interesting natural
molecule."
About Therapeutic Solutions International,
Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
www.therapeuticsolutionsint.com
and
e-commerce at www.youcanordernow.com.
[1] Conboy et al.
Rejuvenation of aged progenitor cells by exposure to a young
systemic environment. Nature. 2005 Feb 17;433(7027):760-4. https://www.ncbi.nlm.nih.gov/pubmed/15716955
[2]
Katsimpardi
et al.
Vascular and neurogenic rejuvenation of the aging mouse brain by
young systemic factors. Science. 2014 May 9;344(6184):630-4.
https://www.ncbi.nlm.nih.gov/pubmed/24797482
[3]
Castellano et al.
Human umbilical cord plasma proteins revitalize hippocampal
function in aged mice. Nature 2017 Apr 27;544(7651):488-492.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586222/
[4]
https://www.globenewswire.com/news-release/2019/01/14/1691086/0/en/Therapeutic-Solutions-International-Announces-Preliminary-Data-for-Immune-Stimulation-in-Advanced-Cancer-Patients-by-Commercially-Available-Product.html
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION